Publication:
Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.

No Thumbnail Available

Date

2018

Authors

Argüelles Arias, Federico
Hinojosa Del Val, Joaquín
Vera Mendoza, Isabel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.

Description

MeSH Terms

Anti-Inflammatory Agents
Biosimilar Pharmaceuticals
Humans
Inflammatory Bowel Diseases
Infliximab
Practice Guidelines as Topic

DeCS Terms

CIE Terms

Keywords

Citation